Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disulfiram in Resectable High-Grade Glioma
NCT07719127Phase 1Not yet recruiting
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of disulfiram in glioma, sponsored by Case Comprehensive Cancer Center. Primary endpoints: Reduction in Complement Immunosuppressive program up to 14 days and Reduction in Scavenger Immunosuppressive program up to 14 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
disulfiram
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07719127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07719127.